Venlafaxine

Venlafaxine has been studied in 18 papers since 2016: 5 trials and 5 observational studies in people, 1 in animals, 7 reviews; 10 in the past year. It is an approved medicine. The newest paper, Oct 30, 2026: “Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis”.

InterventionApproved 1993

18 papers study it9 more mention it9 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 27 papers on venlafaxine

At a glance

The findings reach people, from one lab or study. 5 independent labs in 3 countries; 91 trials, none about aging, 42 with no results posted.

“Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites.”
Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trialBreast cancer (Tokyo, Japan)2026doi:10.1007/s12282-026-01828-5

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 5 independent labs in 3 countries
  • 91 trials, none about aging, 42 with no results posted
  • Funders: China Pharmaceutical University and others
  • Human trial5
  • Humans5
  • Animals1

Studies in people

1 study gave venlafaxine to people and measured what changed.

What changedDesignPeopleSource

down: Decreases hot flash score-49.8% (P < 0.001)

no change: Has no effect on tamoxifen

Trial4 weeks17 peopleWomenPatient cohortsBreast cancer (Tokyo, Japan), Feb 5, 2026

What did studies of venlafaxine find?

8

Studies of venlafaxine measured 8 outcomes, among them vasomotor symptoms, depressive symptoms and tamoxifen.

Vasomotor symptoms

downin humans1

1 study
  1. Venlafaxine decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.42, 95% CI -0.76 to -0.07).

    “venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebo75 mgfemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

More on Vasomotor symptoms

Depressive symptoms

downin humans1

1 study
  1. Venlafaxine decreases depressive symptoms in patients with major depressive disorder.

    “Escitalopram and venlafaxine effectively manage depressive symptoms and vasomotor instability in patients with major depressive disorder.”

    Reviewin patients with major depressive disorderfemales

    FIGO best practice recommendations for the mental health of women at menopausal age

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

More on Depressive symptoms

Tamoxifen

no changein humans1

1 study
  1. Venlafaxine showed no clear effect on tamoxifen in humans.

    “Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites.”

    Human trial37.5 mg/day4 weeksfemalesn = 18

    Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial

    Breast cancer (Tokyo, Japan)

More on Tamoxifen

Hot flash score

downin humans1

1 study
  1. Venlafaxine decreases hot flash score in humans (-49.8% (P < 0.001)).

    “At Week 4, hot flash scores declined by 49.8% from baseline (P < 0.001).”

    Human trial37.5 mg/day4 weeksfemalesn = 17

    Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial

    Breast cancer (Tokyo, Japan)

PI3K–AKT signaling

upin animals1

1 study
  1. Venlafaxine activates PI3K–AKT signaling.

    “venlafaxine upregulated cortical catechol-O-methyltransferase expression and activity via activating phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway”

    Animalscerebral cortex

    Venlafaxine upregulates cortical catechol-O-methyltransferase expression and activity in rats and mice

    Drug metabolism and disposition: the biological fate of chemicals

More on PI3K–AKT signaling

S-adenosylmethionine

downin animals1

1 study
  1. Venlafaxine decreases S-adenosylmethionine (chronic in vivo exposure).

    “decreases in the methyl donor S-adenosylmethionine (SAM) levels”

    Animalschronic in vivo exposurecerebral cortex8 days

    Venlafaxine upregulates cortical catechol-O-methyltransferase expression and activity in rats and mice

    Drug metabolism and disposition: the biological fate of chemicals

More on S-adenosylmethionine

Catechol-O-methyltransferase

upin animals1

1 study
  1. Venlafaxine increases catechol-O-methyltransferase (chronic in vivo exposure).

    “Chronic in vivo exposure to venlafaxine for 8 days led to increases in cerebral COMT expression and activity”

    Animalschronic in vivo exposurecerebral cortex8 days

    Venlafaxine upregulates cortical catechol-O-methyltransferase expression and activity in rats and mice

    Drug metabolism and disposition: the biological fate of chemicals

Alzheimer's disease progression

downin humans1HR 0.72

1 study
  1. Venlafaxine is linked with lower alzheimer's disease progression in humans (mild cognitive impairment) (HR 0.72 [0.62, 0.85]).

    “venlafaxine (vs. escitalopram: difference: ‐0.04 [‐0.07, ‐0.02], P=0.002, HR: 0.72 [0.62, 0.85], P<0.001)”

    Humansmild cognitive impairment

    Critical real‐world patient data observation of repurposable drugs from Alzheimer's disease drug development pipeline using Target Trial Emulation

    AAIC 2025 abstract

What is venlafaxine linked with?

1

Studies link venlafaxine with Alzheimer's disease.

Alzheimer's disease

downin humans1HR 0.72

1 study
  1. Venlafaxine is linked with a lower risk of Alzheimer's disease in humans (active comparator vs escitalopram, MCI cohort) (HR 0.72, 95% CI 0.62–0.84).

    “venlafaxine (vs escitalopram; 0.72, 95% CI [0.62, 0.84])”

    Humansactive comparator vs escitalopram, MCI cohort

    Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation

    Alzheimer's & dementia (New York, N. Y.)

More on Alzheimer's disease

Has venlafaxine been tested in people?

0 of 91 about aging

Yes: 5 trials and 5 observational studies in people have been published, and 91 trials are registered.

Approved

Repurposing

All 38

In trials

  • Roux-en-y gastric bypass

    Phase 4Completed2 trials

  • Obstructive sleep apnea of adult

    Phase 4Completed1 trial

  • Physiological sexual dysfunction

    Phase 4Completed1 trial

  • Sleeve gastrectomy

    Phase 4Completed1 trial

  • Prostatic neoplasm

    Phase 3Terminated2 trials

  • Bariatric surgery

    Phase 1Completed1 trial

Stopped

  • NCT01436643TerminatedDepression

    Due to slow enrollment the study was terminated early

  • NCT00354432TerminatedHot flashes

    Stopped by the DSMB for lack of effect per interim stopping rule.

  • NCT05603104TerminatedSchizophrenia

    The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.

  • NCT00211809Terminated

    low enrollment

Who is developing venlafaxine?

1 company: Teva Pharmaceuticals USA.

Companies

Trial sponsors

Funding

1 grant since 2022

National Institute for Health Research£2M

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 2Jan 2026: 2Feb 2026: 1Mar 2026: 3Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 2Nov 2026: 010 papers in 12 months

See all 27 papers on venlafaxine